Suppr超能文献

冰岛急性磷酸盐肾病的发病情况和转归。

Incidence and outcome of acute phosphate nephropathy in Iceland.

机构信息

Department of Internal Medicine, Landspitali University Hospital, Reykjavik, Iceland.

出版信息

PLoS One. 2010 Oct 19;5(10):e13484. doi: 10.1371/journal.pone.0013484.

Abstract

BACKGROUND

Oral sodium phosphate solutions (OSPS) are widely used for bowel cleansing prior to colonoscopy and other procedures. Cases of renal failure due to acute phosphate nephropathy following OSPS ingestion have been documented in recent years, questioning the safety of OSPS. However, the magnitude of the problem remains unknown.

METHODOLOGY/PRINCIPAL FINDINGS: We conducted a population based, retrospective analysis of medical records and biopsies of all cases of acute phosphate nephropathy that were diagnosed in our country in the period from January 2005 to October 2008. Utilizing the complete official sales figures of OSPS, we calculated the incidence of acute phosphate nephropathy in our country. Fifteen cases of acute phosphate nephropathy were diagnosed per 17,651 sold doses of OSPS (0.085%). Nine (60%) were women and mean age 69 years (range 56-75 years). Thirteen patients had a history of hypertension (87%) all of whom were treated with either ACE-I or ARB and/or diuretics. One patient had underlying DM type I and an active colitis and one patient had no risk factor for the development of acute phosphate nephropathy. Average baseline creatinine was 81.7 µmol/L and 180.1 at the discovery of acute renal failure, mean 4.2 months after OSPS ingestion. No patient had a full recovery of renal function, and at the end of follow-up, 26.6 months after the OSPS ingestion, the average creatinine was 184.2 µmol/L. The average eGFR declined from 73.5 ml/min/1.73 m(2) at baseline to 37.3 ml/min/1.73 m(2) at the end of follow-up. One patient reached end-stage renal disease and one patient died with progressive renal failure.

CONCLUSION/SIGNIFICANCE: Acute phosphate nephropathy developed in almost one out of thousand sold doses of OSPS. The consequences for kidney function were detrimental. This information can be used in other populations to estimate the impact of OSPS. Our data suggest that acute phosphate nephropathy may be greatly underreported worldwide.

摘要

背景

口服磷酸钠盐溶液(OSPS)广泛用于结肠镜检查及其他操作前的肠道清洁。近年来,有病例报道因口服 OSPS 导致急性磷酸盐肾病而引起肾衰竭,这对 OSPS 的安全性提出了质疑。然而,其问题的严重程度仍不清楚。

方法/主要发现:我们对 2005 年 1 月至 2008 年 10 月期间我国诊断的所有急性磷酸盐肾病病例的病历和活检进行了基于人群的回顾性分析。利用 OSPS 的完整官方销售数据,我们计算了我国急性磷酸盐肾病的发病率。每销售 17651 份 OSPS 就有 15 例(0.085%)诊断为急性磷酸盐肾病。9 例(60%)为女性,平均年龄 69 岁(56-75 岁)。13 例患者有高血压病史(87%),均接受 ACE-I 或 ARB 和/或利尿剂治疗。1 例患者患有 1 型糖尿病和活动性结肠炎,1 例患者无急性磷酸盐肾病的发展危险因素。基线肌酐平均为 81.7µmol/L,急性肾衰竭发现时为 180.1µmol/L,OSPS 服用后平均 4.2 个月。没有患者肾功能完全恢复,在 OSPS 服用后随访结束时(18 个月),平均肌酐为 184.2µmol/L。平均 eGFR 从基线时的 73.5ml/min/1.73m2 下降到随访结束时的 37.3ml/min/1.73m2。1 例患者发展为终末期肾病,1 例患者死于进行性肾衰竭。

结论/意义:OSPS 每销售 1000 份中就有 1 份发展为急性磷酸盐肾病。对肾功能的影响是有害的。这些信息可用于其他人群以估计 OSPS 的影响。我们的数据表明,急性磷酸盐肾病在全球范围内可能被大大低估。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8636/2957439/eea07816cc50/pone.0013484.g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验